Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Gene Expression Profiling Reveals Two Overarching Types of Anaplastic Large Cell Lymphoma with Distinct Targetable Biology: An L.L.M.P.P. Study

Blood (2023) 142 (Supplement 1): 847.

https://doi.org/10.1182/blood-2023-186969

Published: 2023

Journal Articles

GATA-3 Dependent Gene Transcription Is Impaired upon HDAC Inhibition

Xiangrong Geng, Chenguang Wang, Thilini Perera, Badeia Saed, Ying Hu, Ashley Wolfe, John C Reneau, Carlos A. Murga-Zamalloa, Ryan A. Wilcox

Blood (2023) 142 (Supplement 1): 4357.

https://doi.org/10.1182/blood-2023-172509

Published: 2023

Journal Articles

Xpo-1 Antagonism Transcriptionally Reprograms and Is a Therapeutic Vulnerability in GATA-3 Driven T-Cell Lymphomas

Chenguang Wang, Nermin Kady, Ashley Wolfe, Ira Maine, Suhaib Abdelrahman, Vanessa Perez Silos, Carlos A. Murga-Zamalloa, Ryan A. Wilcox

Blood (2023) 142 (Supplement 1): 1648.

https://doi.org/10.1182/blood-2023-187231

Published: 2023

Journal Articles

Xpo-1 Antagonism Impairs CSF-1R Expression and Depletes Lymphoma-Associated Macrophages in T-Cell Lymphomas

Nermin Kady, Chenguang Wang, Ashley Wolfe, Ira Maine, Suhaib Abdelrahman, Carlos A. Murga-Zamalloa, Ryan A. Wilcox

Blood (2023) 142 (Supplement 1): 1647.

https://doi.org/10.1182/blood-2023-186364

Published: 2023

Journal Articles

Pre-Clinical Activity of Navitoclax in TCR-Driven and Non-ALCL Mature T-Cell Lymphomas

Xiangrong Geng, Chenguang Wang, Ashley Wolfe, Ira Maine, Suhaib Abdelrahman, Carlos A. Murga-Zamalloa, Ryan A. Wilcox

Blood (2023) 142 (Supplement 1): 4146.

https://doi.org/10.1182/blood-2023-174520

Published: 2023

Journal Articles

A Multi-Center Study: Outcomes Among Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with CD20 Loss

Radhika Takiar, Wern Lynn Ng, Eshana Shah, Philip S. Boonstra, Yasmin H. Karimi, Shannon A. Carty, Ryan A. Wilcox, Carlos A. Murga Zamalloa, Grzegorz S. Nowakowski, Tycel J. Phillips

Blood (2022) 140 (Supplement 1): 9510–9511.

https://doi.org/10.1182/blood-2022-158825

Published: 2022

Journal Articles

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Yuqin Song, Ning Ding, Dok Hyun Yoon, John C. Reneau, Ryan A. Wilcox, Won Seog Kim, Youn H. Kim, Michael S. Khodadoust, Tatyana A. Feldman, Costas K. Yannakou, Pratyush Giri, Jonathan E Brammer, Lih-Yun Hsu, Hongwei Yuan, Erik Verner, Suresh Mahabhashyam, Richard A. Miller

Blood (2022) 140 (Supplement 1): 8857–8859.

https://doi.org/10.1182/blood-2022-159177

Published: 2022

Journal Articles

Getting ALK inhibitors SHPshape

Ryan A. Wilcox

Blood (2022) 139 (5): 642–643.

https://doi.org/10.1182/blood.2021014301

Published: 2022

Journal Articles

Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

Steven M. Horwitz, Tatyana A. Feldman, Jing C. Ye, Michael S. Khodadoust, Javier Munoz, Paul A. Hamlin, Youn H. Kim, Ryan A. Wilcox, Manish R. Patel, Greg P. Coffey, Muhtarjan Osman, Jaymes S Holland, Cristina B Guzman, Sonali M. Smith

Blood (2021) 138 (Supplement 1): 622.

https://doi.org/10.1182/blood-2021-148352

Published: 2021

Journal Articles

A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma

Swami P. Iyer, MD, Auris Huen, MD, Bradley Haverkos, MD MPH, MS, Weiyun Z. Ai, Craig Okada, MD PhD, Timothy M. Kuzel, MD, Mary Jo Lechowicz, MD, Juan Pablo Alderuccio, MD, Ann Mohrbacher, MD, Don A. Stevens, MD, Ryan A. Wilcox, MD, Tatyana A. Feldman, MD, Suchitra Sundaram, MD, Deepa Jagadeesh, MDMPH, Nishitha Reddy, MD MSCI, Kasi Viswanath Routhu, PhD, Prajak Barde, MD, Ajit Mohanchandran Nair, PhD

Blood (2020) 136 (Supplement 1): 8–10.

https://doi.org/10.1182/blood-2020-136018

Published: 2020

Journal Articles

Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-135870

Published: 2020

Journal Articles

Risk of Opportunistic Infections in Patients with Bendamustine-Associated Lymphopenia and the Utility of Antimicrobial Prophylaxis

Jayasree Krishnan, MD, Victoria Nachar, PharmD, Bernard Lawrence Marini, PharmD, Anthony J. Perissinotti, PharmD, Tycel J. Phillips, MD, Mark S Kaminski, MD, Shannon A. Carty, MD, Ryan A. Wilcox, MD

Blood (2020) 136 (Supplement 1): 50.

https://doi.org/10.1182/blood-2020-142763

Published: 2020

Journal Articles

Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma

Michael S. Khodadoust, MD PhD, Tatyana A. Feldman, MD, Dok Hyun Yoon, Costas K. Yannakou, MBBS (Hons), FRACP, FRCPA, Dejan Radeski, MBBS, FRACP, FRCPA, Youn H. Kim, MD, Neha Mehta-Shah, MD, Amit Khot, MBBS, MD MRCP, FRCPath, FRACP, Ryan A. Wilcox, MD, Won Seog Kim, MD PhD, Steven M. Horwitz, MD, Joseph J. Buggy, PhD, Andrew Hotson, PhD, Craig M. Hill, PhD, Brian Munneke, PhD, Suresh Mahabhashyam, MD, Richard A. Miller, MD, James W. Janc, PhD, Mehrdad Mobasher, MDMPH

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-137782

Published: 2020

Journal Articles

The Feasibility of Virtual Toxicity Assessments in Lymphoma Patients Receiving Immunochemotherapy

John S. Runge, PhD, Anna B. Brown, PharmD, BCOP, Tycel J. Phillips, MD, Mark S Kaminski, MD, Shannon A. Carty, MD, Ryan A. Wilcox, MD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-134151

Published: 2020

Journal Articles

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Steven M. Horwitz, MD, Tatyana A. Feldman, MD, Brian T. Hess, MD, Michael S. Khodadoust, MD PhD, Youn H. Kim, MD, Javier Munoz, MD MS, FACP, Manish R. Patel, MD, Tycel J. Phillips, MD, Stephen D. Smith, MD, Sonali M. Smith, MD, Ryan A. Wilcox, MD PhD, Matt R. Birrell, Janet M. Leeds, PhD, Pamela B. Conley, PhD, Glenn C. Michelson, MD, Gregory P. Coffey, PhD, John T. Curnutte, MD PhD, Paul A. Hamlin, MD

Blood (2019) 134 (Supplement_1): 466.

https://doi.org/10.1182/blood-2019-123986

Published: 2019

Journal Articles

Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malignancy

Blood (2019) 134 (Supplement_1): 4028.

https://doi.org/10.1182/blood-2019-130223

Published: 2019

Journal Articles

ECP in the spotLIGHT

Ryan A. Wilcox

Blood (2019) 134 (16): 1275–1277.

https://doi.org/10.1182/blood.2019002790

Published: 2019

Journal Articles

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma

Blood (2019) 133 (15): 1664–1676.

https://doi.org/10.1182/blood-2018-09-872549

Published: 2019

Includes: Supplemental data

Journal Articles

Interleukin-2-Inducible T-Cell Kinase (ITK) Inhibitors for the Treatment of T-Cell Lymphoproliferative Disorders

John C. Reneau, MD, Steven R. Hwang, MD, Carlos A. Murga-Zamalloa, MD, Joseph J. Buggy, PhD, James W. Janc, PhD, Ryan A. Wilcox, MD PhD

Blood (2018) 132 (Supplement 1): 4172.

https://doi.org/10.1182/blood-2018-99-110554

Published: 2018

Journal Articles

Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Center Study

Fares Alsawah, MD BS, MS, Samuel A. Merrill, MD PhD, Paula L. Bockenstedt, MD, Erica L. Campagnaro, MD, Sumana Devata, MD, Scott D. Gitlin, MD, Mark S Kaminski, MD, Alice M. Cusick, MD, Tycel J. Phillips, MD, Suman L. Sood, MD, Moshe Talpaz, MD, Albert Thomas Quiery, MD, Philip S Boonstra, PhD, Asra Z. Ahmed, MD, Ryan A. Wilcox, MD PhD

Blood (2018) 132 (Supplement 1): 1119.

https://doi.org/10.1182/blood-2018-99-116854

Published: 2018

NARROW

Gene Expression Profiling Reveals Two Overarching Types of Anaplastic Large Cell Lymphoma with Distinct Targetable Biology: An L.L.M.P.P. Study

GATA-3 Dependent Gene Transcription Is Impaired upon HDAC Inhibition

Xpo-1 Antagonism Transcriptionally Reprograms and Is a Therapeutic Vulnerability in GATA-3 Driven T-Cell Lymphomas

Xpo-1 Antagonism Impairs CSF-1R Expression and Depletes Lymphoma-Associated Macrophages in T-Cell Lymphomas

Pre-Clinical Activity of Navitoclax in TCR-Driven and Non-ALCL Mature T-Cell Lymphomas

A Multi-Center Study: Outcomes Among Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients with CD20 Loss

ITK Inhibitor Induces Dose-Dependent Th1 Skewing in Normal T Cells and Is Active in Refractory T Cell Lymphomas

Getting ALK inhibitors SHPshape

Phase 2a Study of the Dual SYK/JAK Inhibitor Cerdulatinib (ALXN2075) As Monotherapy in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma

A Multi-Center, Open Label, Phase I/II Study to Assess the Safety and Efficacy of Tenalisib Given in Combination with Romidepsin in Patients with Relapsed/Refractory T-Cell Lymphoma

Predictive Factors and Outcomes for Ibrutinib Therapy in Relapsed/Refractory Marginal Zone Lymphoma: A Multicenter Cohort Study

Risk of Opportunistic Infections in Patients with Bendamustine-Associated Lymphopenia and the Utility of Antimicrobial Prophylaxis

Cpi-818, an Oral Interleukin-2-Inducible T-Cell Kinase Inhibitor, Is Well-Tolerated and Active in Patients with T-Cell Lymphoma

The Feasibility of Virtual Toxicity Assessments in Lymphoma Patients Receiving Immunochemotherapy

A Phase 2 Study of the Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Good Tolerability and Clinical Response in Relapsed/Refractory Peripheral T-Cell Lymphoma and Cutaneous T-Cell Lymphoma

Characteristics, Treatment Patterns, and Outcomes in Primary Cutaneous Gamma Delta T Cell Lymphoma (PCGDTCL): A Real World Multi-Institutional Analysis of a Rare Malignancy

ECP in the spotLIGHT

Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma

Interleukin-2-Inducible T-Cell Kinase (ITK) Inhibitors for the Treatment of T-Cell Lymphoproliferative Disorders

Ruxolitinib Is Active and Well Tolerated in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis: Preliminary Results of an Ongoing, Open-Label, Single Center Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only